Digital Healthcare Wins FDA Approval fo...( Unique Retinal Imaging System Allow...),Health

Unique Retinal Imaging System Allows Primary Care Physicians to Capture

Digital Retinal Images

WAKE FOREST, N.C., Sept. 19 /PRNewswire/ -- Digital Healthcare Inc., a retinal risk assessment and disease management company based in Wake Forest, NC, announced today that it has won approval from the U.S. Food and Drug Administration to pre-market its Retasure retinal risk assessment system and its iP(R) technology platform.

Retasure is a simple, affordable solution that allows primary care physicians to capture digital images of diabetic patients' retinas in a non-invasive procedure that takes just a few minutes. The images are then transmitted over a secure, HIPPA compliant network to a board certified ophthalmologist at an accredited reading center for examination and assessment. Results are returned to the primary care physician within 72 hours.

Digital Healthcare has already announced several major contracts with primary diabetes care and ophthalmology providers in several states and is now planning general availability of the Retasure system throughout the United States. Retasure was introduced in the United States earlier this year, and more than one million diabetic patients world-wide receive annual retinal risk assessments using Digital Healthcare software. There are approximately 20 million diabetic patients in the United States, but it is estimated that only about half of them get regular retinal risk assessments.

Retasure offers several advantages to primary care physicians and their patients: It can be operated by non-clinicians; it is non-invasive and requires no dilation; it obtains exceptionally high-quality digital images of the retina using a simple-to-operate fundus camera; it returns results quickly to primary care physicians; and it encourages patient compliance for regular retinal assessment.

Digital Healthcare's iP(R) technology platform is an integrated workflow management engine de
'/>"/>